| __timestamp | MannKind Corporation | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 100244000 | 46425000 |
| Thursday, January 1, 2015 | 29674000 | 81491000 |
| Friday, January 1, 2016 | 14917000 | 94291000 |
| Sunday, January 1, 2017 | 14118000 | 121827000 |
| Monday, January 1, 2018 | 8737000 | 160524000 |
| Tuesday, January 1, 2019 | 6900000 | 200000000 |
| Wednesday, January 1, 2020 | 6248000 | 275000000 |
| Friday, January 1, 2021 | 12312000 | 328100000 |
| Saturday, January 1, 2022 | 19721000 | 463800000 |
| Sunday, January 1, 2023 | 31283000 | 565000000 |
| Monday, January 1, 2024 | 731100000 |
In pursuit of knowledge
In the competitive world of biotechnology, innovation is the lifeblood of success. Over the past decade, Neurocrine Biosciences, Inc. and MannKind Corporation have taken distinct paths in their research and development (R&D) investments. From 2014 to 2023, Neurocrine Biosciences has consistently increased its R&D spending, culminating in a staggering 1,116% growth by 2023. In contrast, MannKind Corporation's R&D investment peaked in 2014 and has since seen a decline, with a 69% reduction by 2023. This divergence highlights Neurocrine's commitment to innovation, as it invests nearly five times more in R&D than MannKind by the end of the period. As the biotech industry continues to evolve, these investment strategies may well determine the future leaders in groundbreaking medical advancements.
R&D Insights: How BeiGene, Ltd. and MannKind Corporation Allocate Funds
Comparing Innovation Spending: Neurocrine Biosciences, Inc. and Alkermes plc
R&D Insights: How Neurocrine Biosciences, Inc. and CRISPR Therapeutics AG Allocate Funds
R&D Spending Showdown: Neurocrine Biosciences, Inc. vs Vericel Corporation
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
Neurocrine Biosciences, Inc. vs Dynavax Technologies Corporation: Strategic Focus on R&D Spending
R&D Insights: How Pharming Group N.V. and MannKind Corporation Allocate Funds
Research and Development: Comparing Key Metrics for Ionis Pharmaceuticals, Inc. and MannKind Corporation
Research and Development Expenses Breakdown: Opthea Limited vs MannKind Corporation
Who Prioritizes Innovation? R&D Spending Compared for Amneal Pharmaceuticals, Inc. and MannKind Corporation
Who Prioritizes Innovation? R&D Spending Compared for Ultragenyx Pharmaceutical Inc. and MannKind Corporation
Analyzing R&D Budgets: MannKind Corporation vs BioCryst Pharmaceuticals, Inc.